General Information of Binding Target of SBP (BTS) (ID: ST00029)
BTS Name
Programmed cell death 1 ligand 1
Synonyms
PD-L1; PDCD1 ligand 1; Programmed death ligand 1; hPD-L1; B7 homolog 1; B7-H1; CD antigen CD274
BTS Type
Protein
Family
Immunoglobulin superfamily;
BTN/MOG family
Gene Name
CD274
Organism
Homo sapiens (Human)
Function
Plays a critical role in induction and maintenance of immune tolerance to self As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) ; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
UniProt ID
Q9NZQ7
UniProt Entry
PD1L1_HUMAN
PFam
PF08205 ; PF07686
Gene ID
29126
Sequence
MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEME
DKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGG
ADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTT
TTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTH
LVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET
Sequence Length
290
Synthetic Binding Protein (SBP) Targeting This BTS
SBP Name Highest Status Mechanism Affinity Application Details Ref
Affibody anti-PD-L1 Z-j1 Research Inhibitor N.A. Cancers [ICD-11: 2D4Z]
SBP Info
[1]
Affibody anti-PD-L1 Z-j2 Research Inhibitor N.A. Cancers [ICD-11: 2D4Z]
SBP Info
[1]
Affibody anti-SARS-CoV-2 M1 Research binder Kd: 68 nM Tools for PD-L1 imaging and therapy
SBP Info
[2]
Affimer anti-PD-L1 AVA-004 Research Inhibitor N.A. Tumors [ICD-11: XH1N44]
SBP Info
[3]
Affimer anti-PD-L1/LAG-3 AVA-021 Research Inhibitor N.A. Tumors [ICD-11: XH1N44]
SBP Info
[3]
Miniprotein anti-PD-L1 DBL1_03 Research binder Kd: 374 nM Research tool
SBP Info
[4]
Miniprotein anti-PD-L1 DBL1_04 Research binder Kd: 120 nM Research tool
SBP Info
[4]
Miniprotein anti-PD-L1 DBL2_02 Research binder Kd: 65 nM Research tool
SBP Info
[4]
Miniprotein anti-PD-L1 DBR3_02 Research binder Kd: 2000 nM Research tool
SBP Info
[4]
Miniprotein anti-PD-L1 DBR3_03 Research binder Kd: 256 nM Research tool
SBP Info
[4]
Monobody BMS-986192 Research Binder N.A. Molecular imaging of PD-L1 expression
SBP Info
[5], [6]
References
1 Screening and production of an affibody inhibiting the interaction of the PD-1/PD-L1 immune checkpoint. Protein Expr Purif. 2020 Feb;166:105520.
2 Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chem Biol. 2022 Jun 17;17(6):1543-1555.
3 Avacta. Product Development Pipeline. 2021.
4 De novo design of protein interactions with learned surface fingerprints
5 Synthesis and Preclinical Evaluation of 68 Ga-labeled Adnectin, 68 Ga-BMS-986192 as a PET Agent for Imaging PD-L1 Expression. J Nucl Med. 2021 Jan 30;jnumed.120.258384.
6 Application of the Gyrolab microfluidic platform to measure picomolar affinity of a PD-L1-binding Adnectin? radioligand for positron emission tomography. Biotechniques. 2020 Sep;69(3):200-205.